id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_bn4i2xcp2je6vhlo2mqowj6qqi	A Nevarez-Sida	PINI6 COST-UTILITY OF CHRONIC HEPATITIS "C" TREATMENT WITH THYMOSIN ALPHA I IN MEXICO	2005	1	.pdf	application/pdf	1127	79	49	PINI6 COST-UTILITY OF CHRONIC HEPATITIS “Câ€? Index claims were outpatient or emergency department visits in 1999–2001 by individuals aged 25–64 with a primary diagnosis of pneumonia, Exclusion criteria: antibiotic prescription, pneumonia diagnosis, or hospitalization in prior 30-days; initial therapy stay (LOS) attributable to complicated skin and soft tissue infections (cSSI) for patients admitted to Thomas Jefferson University discharges in 2003, 1,883 (5.5%) included one of the cSSI diagnosis codes; these encompassed 225 DRGs. The mean cost for DRGs, mean cost of cSSI added $42,563 onto the cost for cases COST-UTILITY OF CHRONIC HEPATITIS "C" TREATMENT OBJECTIVE: To estimate cost-utility of the following alternatives in the treatment of chronic hepatitis C (CHC) in the of life and costs of health care institutions. RESULTS: Triple therapy (peginterferon plus ribavirin plus thymosin alpha-1) was dominant over the rest of alternatives costing OBJECTIVES: This study investigated the effect of using different utilities for a cost-utility analysis comparing peginterferon	./cache/work_bn4i2xcp2je6vhlo2mqowj6qqi.pdf	./txt/work_bn4i2xcp2je6vhlo2mqowj6qqi.txt